Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Cannabinoid / CBD
Cannabinoid

CBD

2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

CBD (cannabidiol) is a non-intoxicating cannabis compound widely sold in oils, edibles, and topicals, with one FDA-approved prescription form (Epidiolex) for certain epilepsies. Hemp-derived CBD has been federally legal since the 2018 Farm Bill, but a 2025 law redefining hemp by total THC takes effect November 12, 2026 and may sweep in some CBD products.

Overview

CBD (cannabidiol) is one of the main compounds in cannabis, but unlike THC it does not produce a high. It is marketed widely as oils, gummies, capsules, and topical products for anxiety, pain, and sleep, though most such uses are not FDA-approved. One purified prescription form, Epidiolex, is FDA-approved to treat certain rare seizure disorders, which is the strongest evidence base for any CBD use.

Source: FDA; MedlinePlus; peer-reviewed literature (NIH/PMC)

Chemistry & mechanism of action

CBD's mechanism is complex and not fully understood. Unlike THC, it does not strongly activate the CB1 cannabinoid receptor, which is why it is non-intoxicating. Instead it interacts with a range of targets — including serotonin 5-HT1A receptors and the endocannabinoid system indirectly — and influences several drug-metabolizing liver enzymes, which is the basis of many of its drug interactions.

Source: peer-reviewed literature (NIH/PMC); FDA

Effects

CBD is generally reported to produce mild calming or anti-anxiety effects without intoxication. Common side effects, most clearly documented at the higher doses used medically, include drowsiness, diarrhea, changes in appetite, and fatigue. Effects from consumer products are inconsistent because potency and actual CBD content vary widely and are often mislabeled.

Source: FDA; peer-reviewed literature (NIH/PMC)

Risks & harms

CBD is not intoxicating and has a relatively favorable safety profile, but it is not risk-free. At higher doses it can cause liver enzyme elevations signaling potential liver injury, a risk flagged in the Epidiolex labeling. Its most important hazard is drug interactions: CBD inhibits liver enzymes that metabolize many medications, and can raise blood levels of drugs including certain blood thinners and anti-seizure medicines, potentially to dangerous levels — anyone on regular medication should treat this as a real interaction risk. The consumer market is poorly regulated: products are frequently mislabeled, containing more, less, or different cannabinoids than stated, and some have been found to contain THC (enough to cause intoxication or a positive drug test) or contaminants such as heavy metals or pesticides. Products are not a substitute for evidence-based medical treatment. Anyone with signs of liver problems (yellowing skin or eyes, severe abdominal pain) or a serious medication interaction should seek medical care; Poison Control at 1-800-222-1222 can advise on exposures. This page has not yet been medically reviewed.

Source: FDA; peer-reviewed literature (NIH/PMC); MedlinePlus

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With cannabis, anxiety or a racing heart usually pass with time. Sit somewhere calm, sip water, and rest — strong edibles in particular can take hours to ease.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

IUPAC name
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diolPubChem PUG-REST · retrieved 2026-06-18
SMILES
CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)OPubChem PUG-REST · retrieved 2026-06-18
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-NPubChem PUG-REST · retrieved 2026-06-18
Synonyms / aliases
cannabidiol, (-)-Cannabidiol, (-)-trans-Cannabidiol, Epidiolex, delta1(2)-trans-Cannabidiol, CARDIOLRX, cannabidiolum, NanoCDB, Melody Cloverstrip, CBD OilPubChem PUG-REST + seed aliases · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Shape
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Color
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Imprint
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Score
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)

Scheduling & legal status

US schedule
Unknown — pending review
International
Unknown — pending review

Dosage

Pending medical reviewer

Sources

← Back to the drug index